We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
How pension funds’ investments have impacted the London Stock Exchange
T-Therapeutics hopes to use genetically engineered rodents and machine learning to discover drugs
German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting
Drugmakers claim that Brussels’ market exclusivity overhaul will reduce R&D investment
Biotech acquisitions this year intended to cement position as market leaders in weight-loss field
It’s the super-science revolutionising skincare. And it might help protect the planet
Bolt-on acquisitions, however interesting, will not get Swiss pharmaceuticals group Roche out of its funk
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
US biotech has been struggling to overcome fall in demand for coronavirus jabs
Rare step comes after Brussels fined US biotech for buying Grail without approval
AstronauTx’s financing is step towards helping millions of people suffering from disease
Cheaper valuations have finally drawn back cash-rich pharmaceutical makers
Companies have yet to provide investors with convincing post-pandemic strategies
London-listed group has signed 50% more clients for its complex cell and gene therapy since end of last year
First example of artificial intelligence helping to accelerate diagnosis of diseases caused by genetic variants
Jonathan Milner says deal materially undervalues Cambridge-based life sciences company
Climate change helps the spread of infectious diseases. Plus: rise in fungal infections highlights risks of antimicrobial resistance; Sydney shows how to almost eliminate HIV transmission; wait goes on for effective Long Covid treatments
Trial finds latest version elicited better immune response than existing jabs
Inceptive’s Jakob Uszkoreit, a pioneer of the technology behind ChatGPT, attracts Nvidia funding to design ‘biological software’
Biotech has been criticised for closing its $8bn acquisition of cancer test company Grail without regulatory approval
Private equity group’s bid for researcher comes as the biomedical market is slowing down post-Covid
Biotech company rejects founder and Republican presidential hopeful’s criticism of US drug regulator
Federal Trade Commission said it secured concessions from pharma company to resolve its competition concerns
Dublin believes that the country’s skill base will attract pharma and medical companies
International Edition
